JNJ
Johnson & Johnson
October 13, 2026 · pre-market
- Rarity
- 2.50
- Peak move
- −7.13%
- Float cap
- $635.2B
Johnson & Johnson is a global healthcare company operating in two segments: Innovative Medicine, which develops prescription drugs for oncology, immunology, neuroscience, cardiovascular and infectious disease, and MedTech, which sells surgical, orthopedic, cardiovascular and vision products. Its customers are hospitals, physicians, clinics, wholesalers and retailers, with roughly half of revenue from the United States. The consumer brands were spun off as Kenvue in 2023.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
13 events · 0 from SEC or newswire · 0 timed with the move- Key event
spinoff_divestitureJohnson & Johnson CFO Joe Wolk said the company leans toward a tax-free spin-off of its DePuy Synthes orthopedics unit, targeting mid-2027, rather than a roughly $20bn sale to Apollo Global Management.
peer_disclosureJohnson & Johnson's Irish DePuy Synthes unit, employing about 1,700 at its Ringaskiddy, Cork site, is the subject of the planned separation; DePuy generated $9.3 billion in 2025 sales and Apollo Global Management has been in talks to acquire it at close to $20 billion.
- Key event
earnings_releaseJohnson & Johnson reported Q3 2026 sales up 5.9% to $25.4bn and adjusted EPS of $2.59, beating the $2.52-$2.53 consensus, while GAAP EPS fell to $0.09 on a talc settlement charge and MedTech sales of $8.64bn missed the $8.74bn target.
- Key event
guidance_changeJohnson & Johnson raised its full-year 2026 guidance to adjusted EPS of $11.05-$11.15 from $10.96-$11.11 and lifted its reported sales outlook to a $101.2bn midpoint, citing portfolio momentum, the Firefly Bio acquisition and a talc litigation charge.
dividend_changeJohnson & Johnson's board declared a fourth-quarter 2026 cash dividend of $1.34 per share, payable December 8, 2026 to shareholders of record on November 24, 2026.
regulatory_approvalThe FDA approved a label update for Cabenuva, the long-acting injectable HIV regimen from ViiV Healthcare and Johnson & Johnson, removing the oral lead-in requirement.
executive_remarkCFO Joseph Wolk said Johnson & Johnson's MedTech segment growth of 2.5% in Q3 2026 was unsatisfactory, with Middle East conflict, European spending cuts and China pricing pressure weighing on the unit.
analyst_ratingStifel Nicolaus maintained a Hold rating on Johnson & Johnson with a $260 price target, and Leerink Partners analyst David Risinger maintained a Buy rating with a $276 target.
product_launchJohnson & Johnson disclosed development details of its OTTAVA robotic surgical system and said the FDA granted U.S. market authorization for the table-integrated soft tissue robotic system.
major_contractTriastek and its subsidiary signed a collaboration and license agreement with Johnson & Johnson to develop novel oral drugs, with J&J's venture arm JJDC taking an equity stake in Triastek.
analyst_ratingBofA Securities raised its price target on Johnson & Johnson to $282 from $278 while maintaining a Neutral rating.
clinical_readoutJohnson & Johnson reported two-year Phase 3 ICONIC-LEAD results for ICOTYDE (icotrokinra), with over 72% of plaque psoriasis patients achieving PASI 90 at Week 112 and 44% complete clearance.
government_contractJohnson & Johnson's agreement with the federal administration trades discounted access to selected medicines through a federal direct-to-consumer site and Medicaid most-favored-nation pricing for exemption from pharmaceutical import tariffs.